Share on StockTwits

Shares of Cara Therapeutics (NASDAQ:CARA) saw a large decrease in short interest in August. As of August 15th, there was short interest totalling 498,943 shares, a decrease of 34.0% from the July 31st total of 755,917 shares, American Banking and Market News reports. Based on an average trading volume of 111,433 shares, the short-interest ratio is presently 4.5 days. Approximately 5.1% of the shares of the stock are short sold.

Cara Therapeutics (NASDAQ:CARA) opened at 10.28 on Thursday. Cara Therapeutics has a 52-week low of $9.648 and a 52-week high of $23.25. The stock has a 50-day moving average of $11.48 and a 200-day moving average of $14.7. The company’s market cap is $232.8 million.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Thursday, August 7th. The company reported ($0.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.27) by $0.11. The company had revenue of $0.96 million for the quarter, compared to the consensus estimate of $0.08 million. Cara Therapeutics’s revenue was down 90.4% compared to the same quarter last year. Analysts expect that Cara Therapeutics will post $-0.84 EPS for the current fiscal year.

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.